Sara M.
- Country
- Sweden
- Department
- Onkologiska Kliniken
Research Overview
- Phase III Evaluation of Trastuzumab Deruxtecan ± Pertuzumab Versus Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Metastatic Breast Cancer
- Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study
- Phase 3 Study of PF-07220060 and Fulvestrant Versus Investigator's Choice in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Post-CDK 4/6 Inhibitor Therapy
Data & Insights
Has run more than one trial at 152 of 369 partner sites.
Specializations
Advanced Breast Cancer Treatment
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative advanced breast cancer, with particular focus on developing therapeutic strategies for metastatic disease stages.
- Novel combination therapies with endocrine agents
- Treatment strategies for disease progression
- Management of metastatic breast cancer
The investigator's work encompasses both first-line and subsequent treatment approaches for advanced breast cancer.
HER2-Positive Breast Cancer
The investigator conducts research in HER2-positive metastatic breast cancer treatment, exploring innovative therapeutic combinations and targeted approaches.
- First-line treatment optimization
- Novel antibody-drug conjugates
- Combination therapeutic strategies
Their research focuses on improving treatment outcomes for patients with HER2-positive disease.
Early-Stage Breast Cancer
Research interests include early-stage breast cancer treatment, particularly in patients with specific genetic and receptor status profiles.
- Adjuvant therapy development
- BRCA-mutated breast cancer
- Endocrine therapy optimization
The investigator explores therapeutic interventions for early-stage disease with various molecular subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.